FDA warns Skin PS Brands that Dark Spot Fix, a hydroquinone skin-lightening drug, is an unapproved and misbranded new drug.
What happened
FDA reviewed the product label and the website Slmdskincare.com, where Dark Spot Fix is sold. The label lists hydroquinone 2% as the active ingredient and calls it a skin lightener; website claims call it depigmenting. FDA said no approved new drug application is in effect, so the product is an unapproved new drug and misbranded.
What FDA found
FDA says Dark Spot Fix is an unapproved new drug because no FDA-approved drug application is in effect for it.
section 505(a) of the FD&C Act, 21 U.S.C. 355(a)FDA says the product is misbranded under the nonprescription drug rules in section 505G because it does not meet those rules and has no approved application.
section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)FDA says skin bleaching drugs with hydroquinone are not generally recognized as safe and effective under a proposed rule, so this product is treated as a new drug.
section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4)
What FDA wants
FDA asks Skin PS Brands to respond in writing within 15 working days, state what it has done to correct the violations and prevent recurrence, and explain any delay with a completion schedule.
Who should pay attention
- skincare brands selling skin-lightening products
- online retailers and distributors of OTC skin care
- contract manufacturers making hydroquinone-containing products
This is a summary. Read the original letter on fda.gov.